

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6504817

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MASAHITO SHIMOJO	12/22/2020
SATOSHI OBIKA	12/21/2020
YUYA KASAHARA	12/22/2020
TAKAO SUZUKI	12/21/2020
MASAKI YAMAGAMI	12/21/2020
TADASHI UMEMOTO	12/21/2020

RECEIVING PARTY DATA

Name:	OSAKA UNIVERSITY
Street Address:	1-1, YAMADAOKA, SUITA-SHI,
City:	OSAKA
State/Country:	JAPAN
Postal Code:	565-0871
Name:	NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION
Street Address:	7-6-8, SAITO-ASAGI, IBARAKI-SHI,
City:	OSAKA
State/Country:	JAPAN
Postal Code:	567-0085
Name:	LUXNA BIOTECH CO., LTD.
Street Address:	2-8, YAMADAOKA, SUITA-SHI,
City:	OSAKA
State/Country:	JAPAN
Postal Code:	565-0871

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17261653

CORRESPONDENCE DATA

Fax Number: (216)621-6165

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent***PATENT**

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 216-621-1113
Email: cbader@rennerotto.com
Correspondent Name: RENNER OTTO BOISSELLE & SKLAR, LLP
Address Line 1: 1621 EUCLID AVENUE
Address Line 2: NINETEENTH FLOOR
Address Line 4: CLEVELAND, OHIO 44115

ATTORNEY DOCKET NUMBER:	NANJ.1PUS01
NAME OF SUBMITTER:	THOMAS W. ADAMS
SIGNATURE:	/thomaswadams/
DATE SIGNED:	01/20/2021
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 12

source=Executed_Assignment_Osaka_University#page1.tif
source=Executed_Assignment_Osaka_University#page2.tif
source=Executed_Assignment_Osaka_University#page3.tif
source=Executed_Assignment_Osaka_University#page4.tif
source=Executed_Assignment_National_Institutes_of_Biomedical#page1.tif
source=Executed_Assignment_National_Institutes_of_Biomedical#page2.tif
source=Executed_Assignment_National_Institutes_of_Biomedical#page3.tif
source=Executed_Assignment_National_Institutes_of_Biomedical#page4.tif
source=Executed_Assignment_Luxna#page1.tif
source=Executed_Assignment_Luxna#page2.tif
source=Executed_Assignment_Luxna#page3.tif
source=Executed_Assignment_Luxna#page4.tif

Attorney Docket No. NANJ.1PUS01

COMBINED DECLARATION AND ASSIGNMENT FOR UTILITY OR DESIGN PATENT APPLICATION

US RIGHTS ONLY **US AND FOREIGN RIGHTS**

Title of Invention: SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE

As a below named inventor, I hereby declare that this declaration and assignment are directed to:

Application No. (<i>Express Mail Label No.</i>)	
Filing Date (<i>Deposit Date</i>)	
Amended on (<i>if applicable</i>)	

or, if no application is identified above, the attached application.

DECLARATION

The above application was made or authorized to be made by me.

I believe that I am the original or an original joint inventor of a claimed invention in the application.

My residence, mailing address and citizenship are as stated below next to my name.

I have reviewed and understand the contents of the application, including the claims.

I hereby acknowledge that any willful false statement made in this declaration is punishable under Section 1001 of Title 18 of the United States Code by fine or imprisonment of not more than five (5) year, or both.

DUTY OF DISCLOSURE

I hereby acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. § 1.56, which in pertinent part states that information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) it refutes, or is inconsistent with, a position the applicant takes in: (i) opposing an argument of unpatentability relied on by the Office, or (ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

ASSIGNMENT

For good and valuable consideration, receipt of which is hereby acknowledged, I have sold and assigned and hereby sell and assign to:

Assignee(s)	Address
Osaka University	1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan
National Institutes of Biomedical Innovation, Health and Nutrition	7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan

Assignee(s)	Address
Luxna Biotech Co., Ltd.	2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan

[If more than one assignee is listed, each owns an undivided equal share in the application and underlying invention so far as concerns the United States unless otherwise indicated or agreed to by the assignees.]

Add

Remove

and the successors and assigns thereof, the entire right, title and interest to said invention so far as concerns the United States and the Territories and Possessions thereof, including the right to claim priority, and said application and all Letters Patent of the United States to be obtained on said application, and any related applications including any nonprovisional application, continuation, division, renewal, substitute or reissue thereof, for the full term or terms for which the same may be granted, and any U.S. nonprovisional, U.S. provisional and/or U.S. national phase patent application on which priority is claimed.

If the U.S. application number and filing date are not set forth above, authorization is hereby given for any attorney of record in the subject patent application to insert below the application number and filing date information for this application when that information becomes available.


Application No.	17/261,653
Filing Date	January 20, 2021

I hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into that would conflict with this assignment and sale.

I further covenant that Assignee(s) will, upon request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent as may be known and accessible to me and will testify as to the same in any proceeding related thereto and will promptly execute and deliver to Assignee(s), or the legal representative thereof, any and all papers, instruments or affidavits required to apply for, obtain, maintain and enforce said application, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof.

I agree that this assignment shall be construed in accordance with the law of the appropriate jurisdiction within the United States, and without regard to its conflicts of laws provisions.

Legal Name of inventor:	Masahito SHIMOJO		
Inventor's signature:	<i>Masahito Shimajo</i>	Date:	12/22/2020
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Satoshi OBIKA		
Inventor's signature:		Date:	12/21/2020
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Yuya KASAHARA		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o National Institutes of Biomedical Innovation, Health and Nutrition 7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan		
Legal Name of Inventor:	Takao SUZUKI		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Masaki YAMAGAMI		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Tadashi UMEMOTO		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Add

Remove

Attorney Docket No. NANJ.1PUS01

COMBINED DECLARATION AND ASSIGNMENT FOR UTILITY OR DESIGN PATENT APPLICATION

US RIGHTS ONLY **US AND FOREIGN RIGHTS**

Title of Invention: SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE

As a below named inventor, I hereby declare that this declaration and assignment are directed to:

Application No. (<i>Express Mail Label No.</i>)	
Filing Date (<i>Deposit Date</i>)	
Amended on (<i>if applicable</i>)	

or, if no application is identified above, the attached application.

DECLARATION

The above application was made or authorized to be made by me.

I believe that I am the original or an original joint inventor of a claimed invention in the application.

My residence, mailing address and citizenship are as stated below next to my name.

I have reviewed and understand the contents of the application, including the claims.

I hereby acknowledge that any willful false statement made in this declaration is punishable under Section 1001 of Title 18 of the United States Code by fine or imprisonment of not more than five (5) year, or both.

DUTY OF DISCLOSURE

I hereby acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. § 1.56, which in pertinent part states that information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) it refutes, or is inconsistent with, a position the applicant takes in: (i) opposing an argument of unpatentability relied on by the Office, or (ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

ASSIGNMENT

For good and valuable consideration, receipt of which is hereby acknowledged, I have sold and assigned and hereby sell and assign to:

Assignee(s)	Address
Osaka University	1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan
National Institutes of Biomedical Innovation, Health and Nutrition	7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan

Assignee(s)	Address
Luxna Biotech Co., Ltd.	2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan

[If more than one assignee is listed, each owns an undivided equal share in the application and underlying invention so far as concerns the United States unless otherwise indicated or agreed to by the assignees.]

Add

Remove

and the successors and assigns thereof, the entire right, title and interest to said invention so far as concerns the United States and the Territories and Possessions thereof, including the right to claim priority, and said application and all Letters Patent of the United States to be obtained on said application, and any related applications including any nonprovisional application, continuation, division, renewal, substitute or reissue thereof, for the full term or terms for which the same may be granted, and any U.S. nonprovisional, U.S. provisional and/or U.S. national phase patent application on which priority is claimed.

If the U.S. application number and filing date are not set forth above, authorization is hereby given for any attorney of record in the subject patent application to insert below the application number and filing date information for this application when that information becomes available.

Application No.	17/261,653
Filing Date	January 20, 2021

I hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into that would conflict with this assignment and sale.

I further covenant that Assignee(s) will, upon request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent as may be known and accessible to me and will testify as to the same in any proceeding related thereto and will promptly execute and deliver to Assignee(s), or the legal representative thereof, any and all papers, instruments or affidavits required to apply for, obtain, maintain and enforce said application, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof.

I agree that this assignment shall be construed in accordance with the law of the appropriate jurisdiction within the United States, and without regard to its conflicts of laws provisions.

Legal Name of Inventor:	Masahito SHIMOJO		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Satoshi OBIKA		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Yuya KASAHARA		
Inventor's signature:	<i>Yuya Kasahara</i>	Date:	12/22/2020
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o National Institutes of Biomedical Innovation, Health and Nutrition 7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan		
Legal Name of Inventor:	Takao SUZUKI		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Masaki YAMAGAMI		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Tadashi UMEMOTO		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Add

Remove

Attorney Docket No. NANJ.1PUS01

COMBINED DECLARATION AND ASSIGNMENT FOR UTILITY OR DESIGN PATENT APPLICATION

US RIGHTS ONLY **US AND FOREIGN RIGHTS**

Title of Invention: **SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE**

As a below named inventor, I hereby declare that this declaration and assignment are directed to:

Application No. (<i>Express Mail Label No.</i>)	
Filing Date (<i>Deposit Date</i>)	
Amended on (<i>if applicable</i>)	

or, if no application is identified above, the attached application.

DECLARATION

The above application was made or authorized to be made by me.

I believe that I am the original or an original joint inventor of a claimed invention in the application.

My residence, mailing address and citizenship are as stated below next to my name.

I have reviewed and understand the contents of the application, including the claims.

I hereby acknowledge that any willful false statement made in this declaration is punishable under Section 1001 of Title 18 of the United States Code by fine or imprisonment of not more than five (5) year, or both.

DUTY OF DISCLOSURE

I hereby acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. § 1.56, which in pertinent part states that information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) it refutes, or is inconsistent with, a position the applicant takes in: (i) opposing an argument of unpatentability relied on by the Office, or (ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

ASSIGNMENT

For good and valuable consideration, receipt of which is hereby acknowledged, I have sold and assigned and hereby sell and assign to:

Assignee(s)	Address
Osaka University	1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan
National Institutes of Biomedical Innovation, Health and Nutrition	7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan

Assignee(s)	Address
Luxna Biotech Co., Ltd.	2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan

[If more than one assignee is listed, each owns an undivided equal share in the application and underlying invention so far as concerns the United States unless otherwise indicated or agreed to by the assignees.]

Add

Remove

and the successors and assigns thereof, the entire right, title and interest to said invention so far as concerns the United States and the Territories and Possessions thereof, including the right to claim priority, and said application and all Letters Patent of the United States to be obtained on said application, and any related applications including any nonprovisional application, continuation, division, renewal, substitute or reissue thereof, for the full term or terms for which the same may be granted, and any U.S. nonprovisional, U.S. provisional and/or U.S. national phase patent application on which priority is claimed.

If the U.S. application number and filing date are not set forth above, authorization is hereby given for any attorney of record in the subject patent application to insert below the application number and filing date information for this application when that information becomes available.

Application No.	17/261,653
Filing Date	January 20, 2021


I hereby covenant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into that would conflict with this assignment and sale.

I further covenant that Assignee(s) will, upon request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent as may be known and accessible to me and will testify as to the same in any proceeding related thereto and will promptly execute and deliver to Assignee(s), or the legal representative thereof, any and all papers, instruments or affidavits required to apply for, obtain, maintain and enforce said application, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof.

I agree that this assignment shall be construed in accordance with the law of the appropriate jurisdiction within the United States, and without regard to its conflicts of laws provisions.

Legal Name of Inventor:	Masahito SHIMOJO		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Satoshi OBIKA		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o OSAKA UNIVERSITY 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Yuya KASAHARA		
Inventor's signature:		Date:	
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o National Institutes of Biomedical Innovation, Health and Nutrition 7-6-8, Saito-Asagi, Ibaraki-shi, Osaka 567-0085 Japan		
Legal Name of Inventor:	Takao SUZUKI		
Inventor's signature:	<i>Takao Suzuki</i>	Date:	2020/12/21
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		
Legal Name of Inventor:	Masaki YAMAGAMI		
Inventor's signature:	<i>Masaki Yamagami</i>	Date:	2020/12/21
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Legal Name of Inventor:	Tadashi UMEMOTO		
Inventor's signature:		Date:	2020/12/21
Residence: (City & State/ Country):	Osaka, Japan		
Post Office Address:	c/o Luxna Biotech Co., Ltd. C907 9F Bldg. C, Techno-Alliance Complex, 2-8, Yamadaoka, Suita-shi, Osaka 565-0871 Japan		

Add

Remove